G. Catteau

发表

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial

L. Cámpora, T. Mrkvan, C. Hervé, 2018, Open Forum Infectious Diseases.

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

P. Hillemanns, M. Dionne, T. Schwarz, 2011, Human vaccines.

Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.

S. Wacholder, A. Hildesheim, R. Herrero, 2014, Vaccine.

Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.

J. Richardus, T. Schwarz, L. Rombo, 2016, Vaccine.

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2014, Human vaccines & immunotherapeutics.

Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.

Tzou-Yien Lin, Li-Min Huang, T. Schwarz, 2012, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women

M. Lehtinen, D. Descamps, C. Pedersen, 2011, International journal of cancer.

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

A. Schneider, T. Schwarz, D. Descamps, 2011, Human vaccines.

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

G. Dubin, A. Carmona, J. García-Sicilia, 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults

J. Richardus, T. Schwarz, G. Sonder, 2018, Human vaccines & immunotherapeutics.

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

M. Einstein, M. Levin, F. Struyf, 2014, Human vaccines & immunotherapeutics.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-adjuvanted Vaccine Coadministered With Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and/or Meningococcal Conjugate Vaccine to Healthy Girls 11 to 18 Years of Age: Results From a Randomized Open Trial

C. Wheeler, M. Pichichero, G. Dubin, 2011, The Pediatric infectious disease journal.

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling

T. Mrkvan, T. Schwarz, L. Rombo, 2019, Open Forum Infectious Diseases.

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

T. Mrkvan, T. Schwarz, L. Rombo, 2020, The Journal of infectious diseases.

Persistence of the Immune Response to an Adjuvanted Herpes Zoster Subunit Vaccine in Healthy Older Adults: Modeling of Vaccine-Induced Immune Response, Data From a 6-Year Follow-Up Study

J. Richardus, T. Schwarz, T. Heineman, 2015 .

Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.

E. Jongert, A. Leach, M. Lievens, 2014, Vaccine.